| Literature DB >> 32021926 |
Francesca Perondi1, Vasilica-Flory Petrescu2, Filippo Fratini1, Claudio Brovida3, Francesco Porciello2, Gianila Ceccherini1, Ilaria Lippi1.
Abstract
Non-permanent central venous catheters (CVCs), are the most commonly used vascular access in veterinary patients undergoing hemodialysis. In human dialysis patients, CVC infection represents a common cause of morbidity and mortality. The aim of this retrospective observational study was to evaluate the prevalence of bacterial colonization of CVCs in dogs submitted to hemodialysis treatment at time of CVC removal. The CVCs of all dogs submitted to hemodialysis (n = 23) at the Veterinary Teaching Hospital ''Mario Modenato'' of the University of Pisa between January 2015 and December 2016 were considered. For all dogs, data regarding signalment, reason for hemodialysis treatment, duration of catheterization (≤15 or >15 days), CVC complications, and 30-day survival were considered. Statistical analysis was performed using Graph Pad Prism™. Five over 23 dogs (22%) showed positive bacterial culture of CVC (+), and 18/23 dogs (78%) negative culture of CVC (-). The most prevalent microorganism was Staphylococcus Spp (3/5; 60%). No significant difference was found in the prevalence of CVC infection according to age, gender, reason for hemodialysis, CVC complications, duration of catheterization, and outcome. No statistically significant difference (p = 0.64) in survival curves was reported at log rank analysis between dogs with CVC - and CVC +. The prevalence of bacterial CVC contamination in our dialysis dogs showed relatively low. Exclusive use of CVC for hemodialysis, good hygiene practice during CVC management, and use of chlorhexidine as an antiseptic should be strongly encouraged.Entities:
Keywords: Bacterial contamination; Biological sciences; Central venous catheter; Dog; Hemodialysis; Internal medicine; Microbiology; Nephrology; Urology; Veterinary medicine
Year: 2020 PMID: 32021926 PMCID: PMC6994843 DOI: 10.1016/j.heliyon.2020.e03224
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Sensitivity profiles of the CVC+.
| Staphylococcus Spp | Staphylococcus Spp | Kleibsiella Pneu | Pseudomonas Viridis | Staph + Streptococcus Spp | |
|---|---|---|---|---|---|
| Amikacin | S | S | S | S | R |
| Amoxicilline | R | R | R | R | R |
| Ampicilline | R | R | R | R | R |
| Amoxi + Clav | R | R | R | R | S |
| Cefalexine | R | R | R | R | S |
| Cefalotine | R | R | R | R | S |
| Cefotaxime | R | R | R | R | S |
| Doxycycline | MS | MS | R | R | S |
| Enrofloxacine | R | R | R | R | R |
| Erythromycin | R | R | R | R | R |
| Gentamicin | R | R | S | MS | MS |
| Streptomycin | R | R | R | R | R |
| Tetracycline | R | R | R | R | S |
| Trimethoprim/Sulfa | R | R | R | R | R |
| Ceftazidime | R | R | R | S | S |
| Ciprofloxacin | R | R | R | R | R |
| Clindamycin | R | NE | R | NE | NE |
| Colistin | R | R | R | S | R |
| Neomycin | R | R | R | R | R |
| Piperacillin | R | R | R | S | R |
| Rifampicin | NE | S | R | R | MS |
| Tobramycin | R | MS | R | S | MS |
S: sensitive; R: resistant; MS: median susceptibility; NE: not tested.
Univariate analysis of factors related to CVC infection.
| Variable | Total number of dogs | CVC + | CVC - | p-value |
|---|---|---|---|---|
| Age (years) | ||||
| 0–1 | 6/23 | 2/6 | 4/6 | 0.64 |
| 2–7 | 9/23 | 2/9 | 7/9 | |
| >8 | 8/23 | 1/8 | 7/8 | |
| Gender | ||||
| Female | 5/23 | 1/5 | 4/5 | 0.99 |
| Male | 18/23 | 4/18 | 14/18 | |
| Reason for HD | ||||
| AKI | 14/23 | 3/14 | 11/14 | 0.84 |
| AKI/CKD | 8/23 | 2/8 | 6/8 | |
| ESRD | 1/23 | 0/1 | 1/1 | |
| Complications | ||||
| C | 12/23 | 3/12 | 9/12 | 0.99 |
| NC | 11/23 | 2/11 | 9/11 | |
| Duration of catheterization (days) | ||||
| ≤15 | 11/23 | 2/11 | 9/11 | 0.99 |
| >15 | 12/23 | 3/12 | 9/12 | |
| Outcome | ||||
| S | 12/23 | 3/12 | 9/12 | 0.99 |
| NS | 11/23 | 2/11 | 9/11 | |
C: complications of CVC; NC: no complications of CVC; S: survivors; NS: non-survivors; HD: hemodialysis.
Antibiotic therapy of dogs with CVC contamination at time of CVC removal.
| Case | Infection agent | Antibiotic therapy |
|---|---|---|
| #1 | Ampicillin + Metronidazole | |
| #2 | Ampicillin + Enrofloxacin | |
| #3 | Doxycycline | |
| #4 | Ampicillin + Enrofloxacin | |
| #5 | Cefazolin + Marbofloxacin |